Stockpolly
Search
Delisting risk
GCTK · NASDAQ · Medical - Instruments & Supplies

GlucoTrack (GCTK)

Clinical developer of a knee-pain biologic and implanted glucose monitoring.

$3.56
Pre-market+0.04 (+0.99%)
At close$3.53(−4.21%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
−21234−32535−4343
Research & development222422233222
111112221221
Selling & marketing000000000000
General & administrative111112111221
Other expenses−4900−72100−9000
Operating income2−12−3−43−25−3−54−3−4−3
−4900−815−30−8000
Interest income000001000000
Interest expense000020000000
Other non-operating income4−9007−14309000
Income before tax−2−2−3−4−5−10−7−5−4−4−4−4
Net income from continuing operations−2−2−3−4−5−10−7−5−4−4−4−4
Net income−2−2−3−4−5−10−7−5−4−4−4−4
EPS, basic−$9.68−$9.05−$11.73−$16.40−$18.18−$21.75−$40.20−$9.62−$4.64−$3.98−$39.75−$11.40
EPS, diluted−$9.68−$9.05−$11.73−$16.40−$18.18−$21.75−$40.20−$9.62−$4.64−$3.98−$39.75−$11.40
Weighted average shares, basic0000000011—0
Weighted average shares, diluted0000000011—0
EBITDA−2−2−3−4−3−11−7−5−4−4−4−4
Depreciation & amortization000000000000
EBIT−2−2−3−4−3−11−7−5−4−4−4−4